ReviewBriefings in bioinformatics2026
Emerging insights into enhancer RNAs: biogenesis, function, mechanism, and disease implication.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancer RNA transcription near segmentation gene enhancers can be analyzed in situ using FISH.G3 (Bethesda, Md.) · 2026Article
- Integrated Analysis of mRNA and microRNA Expression in Corneal Impression Cytology Samples from Patients withInternational journal of molecular sciences · 2026Article
- FOXK1: a multifaceted regulator in metabolic reprogramming and disease progression.Biology direct · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In current years, the molecular mechanisms through which enhancer-derived noncoding RNAs-enhancer RNAs (eRNAs) have been increasingly elucidated. eRNAs are not mere as transcript products but considered as a marker of active enhancers, usually characterized by bidirectional transcription, lack of poly(A) tails and rapid degradation. Multiple lines of evidence have demonstrated eRNAs are involved in a number of regulation processes such as enhancer-promoter (E-P) looping, recruitment of transcriptional co-activators, regulation of RNA polymerase II (Pol II) pause release, and induction of R-loops, thereby enabling precise control of gene expression. Besides, the tissue-specific regulatory mechanisms of eRNAs in diverse diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders are being progressively elucidated, offering potential novel targets for precision diagnosis and therapy. This review systematically synthesizes recent advances in eRNA research, elucidating structural features, transcription processes, functions, regulatory mechanisms, detection, data resources, disease associations and proposing promising prospects for eRNA-targeted precision therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.